Bloomberg scrutinizes drug pricing

Share this article:

A drug pricing analysis conducted for Bloomberg found that prices doubled for dozens of established drugs, sometimes without any corresponding improvement, and that the launch prices of new drugs continue creeping upward.

Moreover, despite the fact that generic drugs comprise 86% of all medicines sold in the US, they have not reduced total spending on prescription medicines, which grew by 11% between 2007 and 2012, the news service found, citing "government data." (By contrast, the IMS Institute for Healthcare Informatics found that total US spending on drugs decreased in 2012.)

One reason for the increases was drugmakers' desire to hike prices on protected products to make up for blockbuster LOEs. Reporter Robert Langreth's analysis also suggests that the recent merger fervor could send prices even higher.

The downside: financial strain on patients. “Every day in my clinic there are patients who start discussing they can't afford this drug or that drug” because it costs too much, wrote one leukemia doctor in an op-ed cited by Langreth.

On the other hand, PhRMA's executive VP for policy, Lori Reilly, noted that “you have to look at the significant contribution that many of these medicines make to improving outcomes,” adding that drug price increases have actually been slower than the growth of other healthcare prices.

Pfizer spokesperson, Andrew Topen, wrote in an e-mail to Bloomberg, “Drug prices reflect many factors such as development risk, the ever-increasing cost of doing business, and their value to the health system.”

Langreth also quotes data from the IMS Institute for Healthcare Informatics showing that last year, increases in prices for existing branded prescription drugs accounted for $20 billion of the industry's 2013 sales growth. For more analysis of those 2013 spending numbers, see The Pharma Report 2014, from the May issue of MM&M.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.